Although indirectly excluding this factor, the tested GLP-1R agonists act as follows: 1) they do not cause a CPP per se as an indication of conditioned aversion (Cagniard and Murphy, 2012), 2) they are used in dosages that are not associated with malaise (Cagniard and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baase et al., 2013; Baisley and Baldo, 2014; Mietlicki-Baase et al., 2017; Rodriguez et al., 2018), 3) they enhance water intake, and 4) they reduce alcohol/drug responses that are unaffected by aversion [for a review, see Shevchouk et al. (2021)]. The gene discussed is GLP1R; the disease is malaise.